HER2-PET Imaging in HER2-low Breast Cancers

计划入组 40 人 · 首次发布于 2024 年 12 月 13 日

Studying Pathways of Resistance in KRAS-driven Cancers

计划入组 58 人 · 首次发布于 2022 年 3 月 9 日

Clinicopathological Parameters of HER2 Low Breast Cancers

计划入组 70 人 · 首次发布于 2024 年 5 月 30 日

C-4

SOS1 / KRAS (KRAS -driven cancer)

Werner inhibitor (MSI-high cancers/sensitive cancers)

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Zymeworks

Canada

Context Therapeutics

United States

Debiopharm Advances Bispecific ADC Development with SunRock Biopharma's Anti-HER2/HER3 Antibody License

Lung Cancer Research Foundation and Boehringer Ingelheim Launch $2.25 Million Initiative to Target HER2-Mutant Lung Cancer

GSK and Hansoh Pharma Advance Next-Generation HER2-Targeted ADC GSK5764227 in Early Clinical Trials